At what enterprise value was VEINCENTRE acquired in 2022?

You can find the full valuation details of VEINCENTRE on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of VEINCENTRE when it was acquired by CBPE CAPITAL?

The exact EV/EBITDA multiple for VEINCENTRE is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was VEINCENTRE acquired by CBPE CAPITAL?

VEINCENTRE was acquired by CBPE CAPITAL in 2022.

What was the EBITDA of VEINCENTRE during the acquisition?

VEINCENTRE's EBITDA is estimated to be in the range of 5M - 25M GBP. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the VEINCENTRE acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the VEINCENTRE deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.cbpe.com/insights/cbpe-capital-completes-investment-in-veincentre

← DATABASE

Home Database Healthcare & PharmaVEINCENTRE

10/2022

VEINCENTRE acquired by CBPE CAPITAL

UNITED KINGDOM Health Providers / Outpatient Care / Aesthetic & Cosmetic Clinics REV 1m GBP - 100m GBP

Context

CBPE Capital has completed a majority investment in Veincentre, acquiring the stake previously held by Palatine Private Equity alongside the company,s founders. This transaction marks a secondary LBO for the specialist clinic group, which saw significant growth under Palatine,s three-year ownership, including the expansion from 7 to 22 clinics. The deal was structured to support the current management team, led by CEO Maurice McLoughlin, in the next phase of their national expansion strategy. The rationale for the acquisition is rooted in the high demand for specialized outpatient vascular services in the UK and Veincentre,s proven, scalable clinical model. CBPE intends to leverage its extensive experience in multi-site healthcare to further increase the group's clinic density across the UK. The operation was supported by a debt advisory from FRP Advisory and commercial due diligence from Candesic.

VEINCENTRE, which reported an EBITDA margin of LOGIN in 2022, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Veincentre is the United Kingdom,s leading specialist provider of minimally invasive treatments for venous insufficiency, primarily focusing on the treatment of varicose veins and venous ulcers. The company operates a high-efficiency business model centered on outpatient procedures performed under local anesthetic, allowing patients to undergo complex vascular treatments with rapid recovery times. Its value proposition is built on clinical excellence, utilizing a dedicated team of consultant vascular surgeons and interventional radiologists to provide specialized care across a growing national network of clinics. Veincentre,s strategy focuses on increasing patient access to high-quality vascular services that are often underserved by traditional healthcare systems. By concentrating exclusively on venous reflux disorders, the group achieves significant operational expertise and high patient satisfaction ratings. The company serves a large addressable market, as venous conditions affect millions of people in the UK, and it continues to expand its geographic footprint to maintain its position as the premier dedicated venous clinical group in the country.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (GBP)

Year

Rev

EBITDA

EBIT

2022

2021

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
06/2023	PARQUEST CAPITAL	IMANEO	FRANCE	Health Providers	Parquest acquired a majority stake in the newly formed Imaneo group from its 70 associate radiologists. The transaction was the result of a competitive process involving both French and international private equity funds, as well as corporate interest from the life sciences sector
11/2022	RADNET	HEART & LUNG IMAGING	UNITED KINGDOM	Health Providers	RadNet, a US-based medical imaging specialist, has acquired a 75% majority stake in Heart & Lung Imaging Limited (HLH), a UK-based teleradiology network focused on detecting and diagnosing lung and cardiovascular diseases
09/2022	ORADIANSE	REVEL	FRANCE	Health Providers	Oradianse, a leading group of radiologists, has acquired a radiology practice in Revel, located in the Haute-Garonne region near Toulouse. This move is part of the company's territorial development strategy, aimed at strengthening its presence in the Occitanie region and consolidating its national network of medical imaging centers
09/2022	EURAZEO	IMAPOLE	FRANCE	Health Providers	Eurazeo has partnered with Bpifrance to complete a major investment of over EUR 50 million in Imapole. This investment marks a strategic turning point in the professionalization of regional medical imaging groups in France
08/2022	FREEMAN SPOGLI	EVERVET PARTNERS	UNITED STATES	Health Providers	Freeman Spogli & Co. made a significant investment in EverVet Partners, partnering alongside existing investor Tailwind Capital while EverVet's founders and management retained meaningful equity stakes
07/2022	LATOUR CAPITAL	PHARMACIE LAFAYETTE - GROUPE HYGIE31	FRANCE	Health Providers	Latour Capital and Bpifrance acquired a majority stake in Hygie31, the holding company of Pharmacie Lafayette, from Five Arrows (Rothschild & Co). The deal aims to accelerate the group's development in France and Europe through organic growth and an ambitious buy-and-build strategy
07/2022	INFRAVIA CAPITAL	UNIVET	FRANCE	Health Providers	InfraVia Capital Partners acquired a minority stake in Univet from Platina Equity Solutions, which had been a partner since 2018. The transaction was structured as a combination of secondary share purchases and a primary capital increase, financed entirely through equity from InfraVia's EUR5 billion European Fund V
07/2022	ANDERA PARTNERS	GROUPE RESONANCE IMAGERIE	FRANCE	Health Providers	R�sonance Imagerie, a prominent French medical imaging group, has secured a major financing package from Andera MidCap, Ardian Private Debt, and Five Arrows Debt Partners. Established in 2011, the group currently operates a network of 15 centers across Paris, �le-de-France, and the Centre-Val-de-Loire region, managing 23 high-tech units including MRIs and scanners
06/2022	EURAZEO	SEVETYS	FRANCE	Health Providers	Eurazeo acquired a majority stake in Sevetys from Ardian, which had previously financed the group's initial rapid expansion. The transaction included a EUR250 million equity injection from Eurazeo to fuel a new phase of aggressive growth
06/2022	TRITON PARTNERS	ESPERI CARE	FINLAND	Health Providers	Triton Partners, via its Triton Smaller Mid Cap Fund II, acquired a majority stake in Esperi Care Oy from a consortium of its former creditors, including Danske Bank, SEB, and Ilmarinen, which remain as minority shareholders

REFERENCES

EBITDA range: 5M - 25M GBP

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of VEINCENTRE by CBPE CAPITAL are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Target: veincentre

Acquirer: cbpe capital